New drug duo aims to save bladders in HER2-positive cancer patients
NCT ID NCT07151560
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests two drugs—disitamab vedotin and toripalimab—as a way to treat HER2-positive muscle-invasive bladder cancer without removing the bladder. About 60 adults with locally advanced cancer will receive different cycles of the combination. The main goal is to see how many patients remain cancer-free with their bladder intact after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- disitamab vedotin and toripalimab
- What this could lead to
- If successful, this combination could offer a way to treat HER2-positive bladder cancer without removing the bladder, improving quality of life.
- What could go wrong
- This is an early phase 2 trial with only 60 people, so results are uncertain. The drugs may cause side effects and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE MUSCLE-INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New symptom diaries aim to improve daily tracking of recurrent UTIs, especially for seniors
- Reminder calls aim to cut missed surgeries
- Promising combo aims to shrink bladder tumors before surgery
- AI overlays put to the test in robotic surgery: will they help or hinder surgeons?
- New registry tracks how bladder testing device works in real life
- New blood test aims to cut unnecessary prostate biopsies